Disease Landscape and Forecast Insights

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…

Clarivate Epidemiology’s coverage of neuronal ceroid lipofuscinosis (NCL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…

The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…

Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are employed: (1)…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics…

China has the greatest burden of hepatitis C virus (HCV) in the world. Chronically infected HCV patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…